Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) has signed a manufacturing agreement with Vermont-based Bio V America.
Under the agreement, Bio V America will manufacture, label, package and supply Pivot’s hemp-derived CBD products in the U.S., where regulations permit.
Bio V America is a U.S.-based importer and distributor of nutraceutical products including vitamins, botanical products and food supplements. The company currently serves North America and Europe.
Pivot to Launch Nationally and Globally
Following the agreement, Pivot said it will start production of its patented and differentiated cannabis formulations using pharmaceutical grade hemp-derived CBD.
Initial products ready to be marketed include two-piece vegan capsules, coated tablets, topical creams, roll-on gels, powder stick packs, and infused beverages. All of the products will be marketed under the “Pivot Naturals” brand.
“Our sales and marketing team is working diligently to detail our new hemp-derived CBD product line to national pharmacy and grocery store chains, and health and nutrition distributors in the U.S. There remains a large unmet need for stable, bioavailable and effective bio-cannabis products that consumers demand for alternative care options,” Pivot CEO Dr. Patrick Frankham said in a statement.
“Adding another U.S.-based manufacturing site is an important inflection point for Pivot. In addition to our manufacturing capabilities in California and Vermont, we await Health Canada’s approval of our pending Standard Processor license for our facility in Montreal. Pivot is well-positioned to launch multiple products, nationally and internationally,” Frankham added.